双糖链蛋白聚糖：一种用于神经肌肉和肌肉骨骼疾病的有前景的新型疗法。 - Suppr

Suppr

超能文献

Biglycan: a promising new therapeutic for neuromuscular and musculoskeletal diseases.

作者信息

Young Marian F, Fallon Justin R

机构信息

National Institutes of Health, Bethesda, MD, USA.

出版信息

Curr Opin Genet Dev. 2012 Aug;22(4):398-400. doi: 10.1016/j.gde.2012.07.008. Epub 2012 Jul 27.

DOI:10.1016/j.gde.2012.07.008

PMID:22841370

Abstract

摘要

相似文献

Biglycan: a promising new therapeutic for neuromuscular and musculoskeletal diseases.

Curr Opin Genet Dev. 2012 Aug;22(4):398-400. doi: 10.1016/j.gde.2012.07.008. Epub 2012 Jul 27.

Biglycan: a multivalent proteoglycan providing structure and signals.

J Histochem Cytochem. 2012 Dec;60(12):963-75. doi: 10.1369/0022155412456380. Epub 2012 Jul 20.

[Analysis of Musculoskeletal Systems and Their Diseases. The role of extracellular matrix and its pathogenesis in musculoskeletal disorders].

Clin Calcium. 2015 Aug;25(8):1155-61.

Non-Glycanated Biglycan and LTBP4: Leveraging the extracellular matrix for Duchenne Muscular Dystrophy therapeutics.

Matrix Biol. 2018 Aug;68-69:616-627. doi: 10.1016/j.matbio.2018.02.016. Epub 2018 Feb 23.

Matrix pathobiology-central roles for proteoglycans and heparanase in health and disease.

FEBS J. 2017 Jan;284(1):7-9. doi: 10.1111/febs.13945.

Biglycan- and Sphingosine Kinase-1 Signaling Crosstalk Regulates the Synthesis of Macrophage Chemoattractants.

Int J Mol Sci. 2017 Mar 9;18(3):595. doi: 10.3390/ijms18030595.

Modulation of canonical Wnt signaling by the extracellular matrix component biglycan.

Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17022-7. doi: 10.1073/pnas.1110629108. Epub 2011 Oct 3.

Protein-anchoring therapy to target extracellular matrix proteins to their physiological destinations.

Matrix Biol. 2018 Aug;68-69:628-636. doi: 10.1016/j.matbio.2018.02.014. Epub 2018 Feb 20.

Cell interactions with the extracellular matrix.

Cell Tissue Res. 2010 Jan;339(1):1-5. doi: 10.1007/s00441-009-0891-x.

Decorin and biglycan expression: its relation with endothelial heterogeneity.

Histol Histopathol. 2011 Apr;26(4):481-90. doi: 10.14670/HH-26.481.

引用本文的文献

Utrophin modulator drugs as potential therapies for Duchenne and Becker muscular dystrophies.

Neuropathol Appl Neurobiol. 2021 Oct;47(6):711-723. doi: 10.1111/nan.12735. Epub 2021 Jun 4.

Proteoglycans in Biomedicine: Resurgence of an Underexploited Class of ECM Molecules.

Front Pharmacol. 2020 Jan 29;10:1661. doi: 10.3389/fphar.2019.01661. eCollection 2019.

Non-Glycanated Biglycan and LTBP4: Leveraging the extracellular matrix for Duchenne Muscular Dystrophy therapeutics.

Matrix Biol. 2018 Aug;68-69:616-627. doi: 10.1016/j.matbio.2018.02.016. Epub 2018 Feb 23.

Decorin and biglycan are necessary for maintaining collagen fibril structure, fiber realignment, and mechanical properties of mature tendons.

Matrix Biol. 2017 Dec;64:81-93. doi: 10.1016/j.matbio.2017.08.004. Epub 2017 Sep 5.

Absence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca2+, Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy.

Physiol Rev. 2016 Jan;96(1):253-305. doi: 10.1152/physrev.00007.2015.

The small leucine-rich proteoglycan BGN accumulates in CADASIL and binds to NOTCH3.

Transl Stroke Res. 2015 Apr;6(2):148-55. doi: 10.1007/s12975-014-0379-1. Epub 2015 Jan 13.

Biglycan modulates angiogenesis and bone formation during fracture healing.

Matrix Biol. 2014 Apr;35:223-31. doi: 10.1016/j.matbio.2013.12.004. Epub 2013 Dec 25.

Gene expression profiling identifies molecular pathways associated with collagen VI deficiency and provides novel therapeutic targets.

PLoS One. 2013 Oct 11;8(10):e77430. doi: 10.1371/journal.pone.0077430. eCollection 2013.

Biological interplay between proteoglycans and their innate immune receptors in inflammation.

FEBS J. 2013 May;280(10):2165-79. doi: 10.1111/febs.12145. Epub 2013 Feb 21.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验